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Although incorporation of amino acid analogs provides a powerful
means of producing new protein structures with interesting func-
tions, many amino acid analogs cannot be incorporated easily by
using the wild-type aminoacyl-tRNA synthetase (aaRS). To be able to
incorporate specific amino acid analogs site-specifically, it is useful to
build a mutant aaRS that preferentially activates the analog com-
pared with the natural amino acids. Experimental combinatorial
studies to find such mutant aaRSs have been successful but can easily
become costly and time-consuming. In this article, we describe the
clash opportunity progressive (COP) computational method for de-
signing a mutant aaRS to preferentially take up the analog compared
with the natural amino acids. To illustrate this COP procedure, we
apply it to the design of mutant Methanococcus jannaschii tyrosyl-
tRNA synthetase (M.jann-TyrRS). Because the three-dimensional
structure for M.jann-TyrRS was not available, we used the STRUCTFAST
homology modeling procedure plus molecular dynamics with contin-
uum solvent forces to predict the structure of wild-type M.jann-TyrRS.
We validate this structure by predicting the binding site for tyrosine
and calculating the binding energies of the 20 natural amino acids,
which shows that tyrosine binds the strongest. With the COP design
algorithm we then designed a mutant tyrosyl tRNA synthetase to
activate O-methyl-L-tyrosine preferentially compared with L-tyrosine.
This mutant [Y32Q, D158A] is similar to the mutant designed with
combinatorial experiments, [Y32Q, D158A, E107T, L162P], by Wang et
al. [Wang, L., Brock, A., Herberich, B. & Schultz, P. G. (2001) Science 292,
498–500]. We predict that the new one will have much greater activity
while retaining significant discrimination between O-methyl-L-
tyrosine and tyrosine.
Proteins are synthesized with precise control over sequence,leading to the vast range of specific structures and functional
properties observed in nature. Even so, the monomer pool for
proteins is limited to the 20 natural amino acids. Increasing the
monomer pool by incorporating new amino acid analogs would
allow development of fascinating new bioderived polymers ex-
hibiting novel but well controlled architectures (1, 2) and could
lead to many interesting applications ranging from incorporating
a fluorescence probe to elucidating specifics of protein structure
and function (3), to incorporating selenium-substituted serine to
facilitate crystallization processes in proteins (4).
The in vivo incorporation of amino acid analogs into proteins is
controlled in large measure by aminoacyl-tRNA synthetases
(aaRS), the class of enzymes that safeguards the fidelity of amino
acid incorporation into proteins. It has been demonstrated that the
wild-type translational apparatus can be used to incorporate some
amino acid analogs into protein (5–11). However, few amino acid
analogs have been incorporated in proteins in vivo and the func-
tionalities of these analogs have been limited. To expand the range
of amino acid analogs that can be incorporated in vivo, it is desirable
to manipulate the activity of the aaRS (12, 13). There has been
steady progress in developing the 21st aaRS-suppressor tRNA pairs
in vivo (14, 15). A big success is the design of a novel orthogonal
tRNA and tyrosyl-tRNA synthetase (TyrRS) from Methanococcus
jannaschii TyrRS (hereafter denoted as M.jann-TyrRS) that incor-
porates O-methyl-L-tyrosine (OMe-Tyr) site-specifically in protein
in response to an amber nonsense codon (16). Such procedures
have tremendous potential to expand the genetic codes in living
cells, but the current combinatorial experiments, which considered
520 mutation trials on 5 residues expected to be at the binding site
of the tyrosine ligand, can become cumbersome. This article
describes the clash opportunity progressive design algorithm (de-
noted as COP) and its application to redesign the binding site of
M.jann-TyrRS for the preferential binding of OMe-Tyr over Tyr.
COP design leads to three mutants expected to bind OMe-Tyr
strongly while discriminating against Tyr. The best mutant [Y32Q,
D158A] is similar to the one [Y32Q, D158A, E107T, L162P],
designed by Wang et al. (16) by using combinatorial experiments.
We predict that the new mutant will have much greater activity
while retaining significant discrimination between OMe-Tyr and
Tyr. The COP procedure should allow the efficient design of
mutant aaRS for incorporation of other new analogs.
Because there is no crystal structure available for M.jann-
TyrRS, we predicted the three-dimensional structure for wild-
type M.jann-TyrRS, by combining the STRUCTFAST sequence
alignment and structure prediction algorithm with molecular
dynamics (MD) including continuum solvent forces. [To select
the 5 residues to modify in their experiments, Wang et al. (16)
used a sequence alignment between M.jann-TyrRS and Bacillus
stearothermophillus TyrRS.] To validate the predicted structure
for M.jann-TyrRS, we use MD plus continuum solvent energies
to demonstrate that Tyr is the preferred ligand over the 19 other
natural amino acids.
Methods
Structure Prediction of Wild-Type M.jann-TyrRS. No crystal structure
is available for M.jann-TyrRS, but three crystal structures (2ts1,
3ts1, and 4ts1) have been reported for B. stearothermophillus TyrRS.
The 2ts1 structure has no bound ligand (17), 3ts1 has the Tyr-AMP
complex bound (17), and 4ts1 has just the Tyr bound (18). By using
the sequence of wild-type M.jann-TyrRS from GenBank (accession
no. Q57834), the three-dimensional structure of the main chain of
M.jann-TyrRS was predicted with the STRUCTFAST (D.D. and
W.A.G., unpublished result) homology modeling technique, with
the 4ts1 crystal structure as template. The sequence identity
between the two sequences is 32.1%. The main chain atoms of the
predicted M.jann-TyrRS structure agree with the corresponding
residues of 4ts1 structure to 0.64 Å coordinates rms difference after
aligning the two structures by using DALI (19).
To place the Tyr ligand in the predicted structure, we matched
the side chain conformation of the five conserved residues
(Tyr-32, Tyr 151, Gln-155, Asp-158, and Gln-173) in the binding
site of M.jann-TyrRS with those conformations from the 4ts1
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crystal structure. The rest of the side chains for the predicted
M.jann-TyrRS were added by using SCWRL version 2.7 (20, 21)
keeping the conformation of the binding site fixed. The resulting
structure was then minimized with MPSIM (22), allowing all
side-chain atoms to move but keeping the main chain fixed. The
MD and minimization calculations with MPSIM used the cell
multipole method (23) to calculate the nonbond interactions.
The protein was described by using the DREIDING force field (24)
with CHARMM22 (25) charges.
For the Tyr ligand and the OMe-Tyr analog, we used Mulliken
charges based on molecular orbitals from quantum mechanics
(QM). The QM calculations were at the HF level with the
6-31G** basis set. Here the geometry was optimized by using
forces calculated with Poisson Boltzmann continuum solvation
(26). QM calculations were carried out with JAGUAR4.0 (Schro¨-
dinger, Portland, OR).
After optimizing the side-chain configurations in the protein,
the energy of the whole protein was minimized with all atoms
movable but with distance constraints on the hydrogen bonds
between the phenolic OH group of the Tyr ligand and the Tyr-32
and Asp-158 side chains. This minimized structure was then used
as the starting structure for annealing MD, where all constraints
were relaxed. Each cycle of annealing MD involved heating the
system from 50 to 600 K and cooling from 600 to 50 K in steps
of 20 K for 0.5 ps. These annealing MD calculations included
solvent forces from the surface-generalized born (SGB) contin-
uum solvation method (27) with a dielectric constant of 80 and
a solvent radius of 1.4 A. The final structure, shown in Fig. 1, was
used to predict the binding of all 20 natural amino acids and to
design the mutant protein.
Docking All 20 Amino Acids to M.jann-TyrRS. In this article we
assume that selectivity in the binding of the amino acid or analog
to the aaRS is necessary for the activation of amino acid by aaRS.
It is known that TyrRS shows selectivity binding tyrosine over 19
other amino acids (28, 29). It has also been shown that the
calculated binding energies correlate well with the measured in
vivo translational activities of a set of Phe analogs to PheRS (30).
Thus, to test over the predicted M.jann-TyrRS sructure 20
natural amino acids were docked into the Tyr binding site. The
resulting 20 mutated protein structures were then minimized fol-
lowed by annealing MD.
The binding energy of each amino acid is calculated as
G  Gprotein Gligand Gprotein  ligand,
[1]
where G(protein  ligand) is the free energy for the protein-
ligand complex, G(protein) is the free energy for the protein, and
G(ligand) is the free energy for the ligand alone. Because the
structure optimizations included solvation forces with the SGB
continuum solvent approximation with the experimental dielectric
constant, we considered that the calculated energies were free
energies (31).
Mutant Design for Preferential Binding of an Amino Acid Analog. We
next describe the COP procedure for structure-based rational
redesign of a binding site. This procedure is useful in predicting
which mutations in the binding site are essential for preferential
binding to a specific ligand. We demonstrate the design strategy
by designing aaRS mutants that activate a specific amino acid
analog preferentially compared to all natural amino acids. The
mutants are selected based on the calculated differential binding
energy of the desired analog against any other potential com-
petitor ligand that might bind to the mutant. For example, in
redesigning TyrRS, we calculate the differential binding energy
of the analog against Tyr and Phe. For cases in which the analog
is much larger than Tyr, then we might consider Trp as a
potential competitor for the redesigned mutant aaRS. The COP
design procedure for designing mutant aaRS comprises the
progressive sequence of steps.
Step 0: Conformation determination. We first determine the
favorable conformations of the analog. We generated the various
rotamers of the ligand over a grid of dihedral angles and
calculated their energies in solution with quantum mechanics.
Step 1: Clash identification. The low energy rotamers from step
0 are then docked into the binding site. To do this the natural amino
acid in the binding pocket was replaced with the energetically
favorable rotamers of the analog while keeping the backbone of the
ligand fixed (in order that the reaction center for the formation of
the aminoacyl–AMP complex would be retained for the analog).
Then the analog rotamer was matched onto the binding site, and the
nonbond energy contributions (Ek) were calculated for each residue
k in the binding pocket, using Eq. 2 [the functional forms for these
Coulomb, Van der Waals, and hydrogen bond nonbond interac-
tions are from the DREIDING force field (24)]:
Ek  
i ,j
 qiqi4rij  De rmrij
12
 2 rmrij
6
 DHB5rHBrij 
12
 6rHBrij 
10cos4 , [2]
where i and j sum over all atoms in the ligand and protein residue
k, of interest, qi and qj are partial charges on atoms i and j,
respectively. rij is the distance between atoms i and j, rm and De
are van der Waals distance and well depth of atoms i and j, and
rHB and DHB are hydrogen bond distance and well depth,
respectively.  is the hydrogen bond angle between atoms i and
j and their bridging hydrogen atom.
Those residues in the wild-type protein having bad clashes
with the analog are marked for mutation. Because the protein
backbone is fixed in step 2, we require that the analog rotamer
should not clash with the backbone of the protein. Analog
rotamers having a severe clash with the protein backbone are
discarded. Table 3 shows an example of the bad clashes of the
analog in the wild-type protein.
Step 2: Relieving clashes with point mutations. Those residues
having bad clashes with the analog are mutated sequentially to all
of the other 19 amino acids. These point mutations use a backbone-
dependent side-chain rotamer library (20). The backbone of the
protein is held fixed in this stage. After each point mutation, the side
chain alone is energy minimized while keeping the rest of the
protein fixed. Then the contribution from this mutated side chain
Fig. 1. Comparison of predicted M.jann-TyrRS (in blue) and the crystal
structure for B. stearothermophillus TyrRS (4ts1) (in yellow). The Tyr ligand is
shown as a ball model.
6580  www.pnas.orgcgidoi10.1073pnas.052150499 Zhang et al.
to the binding energy of both the analog and the wild-type amino
acid are calculated by using Eq. 2. Also, the clashes of this mutated
residue with neighboring residues in the protein are calculated. The
best mutations are selected with a scoring energy function consist-
ing of a weighted sum of the differential nonbond interaction
energy of the mutated residue with the ligand and the analog, and
the nonbond interaction energy of the mutated residue with the rest
of the residues in the protein. Generally the weights are 0.75–1.0 for
ligand–protein interaction, and 0.0–0.25 for protein–protein inter-
actions. We also add desolvation penalty to the energy of the
mutated residue, calculated with the SGB continuum solvent
method with MPSIM. Here we calculate the differential binding
energies for all 20 possible amino acid mutations, as in Table 4. This
procedure is repeated for all of the residues showing a clash in the
binding pocket of the analog (step 1). The mutation candidates for
further consideration are selected based on the scoring energy
between the analog and the natural ligand.
Step 3: Stabilizing point mutations (opportunities). After iden-
tifying candidate mutation for relieving clashes, we then look for
opportunities for mutations in the binding pocket that would
stabilize the analog ligand or disrupt the bonding with the
natural ligand. Thus, we consider residues near the ligand (within
6 Å) and look for residues that might, for example, take
advantage of hydrogen bond donor or acceptor atoms that are
different between the analog and the natural ligand. These
opportunity mutations are selected with the same procedure as
for clash mutations.
Step 4: Combined mutations. Steps 2 and 3 lead to a subset of
mutation candidates that are expected to either relieve clashes
or provide stabilization opportunities to the binding of the
analog in preference to the wild-type ligand. In step 4, we
generate simultaneous mutations from each of the chosen
subsets of mutations. For example, if the clash analysis (step 2)
leads to 3 residues with 2, 3, and 4 candidates and the oppor-
tunity analysis leads to 1 residue with 5 possible mutation
candidates (say for making hydrogen bonds with the analog),
then we would consider 2  3  4  5  120 possible protein
mutants. We generate the best possible rotamer combination for
each of these 120 mutant proteins (optimizing the side chains by
conjugate gradient minimization). Then, after selecting opti-
mum side chains for all 120 cases, the structure of the whole
mutant protein is minimized both with the natural ligand and
with the analog. Finally, the differential binding energy of the
analog to the natural amino acid in the mutant is calculated by
using Eq. 1 with DREIDING force field and including SGB
solvation.
Step 5: Relaxation of the free mutant protein without the ligand.
In step 4, we considered mutations and side-chain conformations
that enhance binding of the protein to the analog. However, it is
possible that some mutations would disrupt the folding of the free
protein when the ligand is not present. Thus, for the best mutants
selected from step 4, we reoptimize the side chains without the
ligand in the binding site. The optimization allows the side chain of
each mutation to go into the part of the binding site normally
occupied by the ligand. In this step, we first reselect the side-chain
conformation from the side-chain library and then optimize the
structure of the full protein with the SGB continuum solvent
procedure. Once the mutant structure is optimized without ligand,
the ligand is then matched on to the binding site and the potential
energy of the resulting structure is minimized with SGB solvation.
This procedure is done for both the analog and the natural ligand
(and any other ligands that might bind to the mutated site). For the
analog ligand this will generally lead to a weaker binding energy
than step 4, because we now include the penalty paid to push the
side chains away from the binding site as the ligand binds. However,
the natural ligand may have a stronger binding energy for step 5.
Thus, the differential binding energy in step 5 will generally be
smaller than in step 4. We denote this differential binding energy
as the ‘‘relaxed protein binding energy,’’ because the mutants were
optimized with no ligand in the binding pocket.
Step 6: Selection. From steps 4 and 5 we select candidate mutants
with both good binding energies to the analog and high differential
binding energies to the natural amino acid. While redesigning aaRS
for binding to a specific analog, it is important that the mutant aaRS
activates only the analog and not any other natural amino acid.
Thus, the best candidate mutants are tested further for binding to
other natural amino acids. To do this testing we dock likely natural
amino acid competitors into both the relaxed and optimized binding
sites, using the procedures described in step1. The binding energy
is calculated for each ligandmutant pair. The mutants are finally
ranked by the difference in binding energies between the analog
and its competitors. The better binding energy is taken either from
the relaxed or the optimized mutant cases.
Steps 1–6 are repeated for other low energy rotamers of the
analog from step 0.
Results and Discussion
Assessment of the Quality of the Predicted Structure for M.jann-TyrRS.
Fig. 1 superimposes the experimental crystal structure of B.
stearothermophillus TyrRS (4ts1) with the predicted structure of
M.jann-TyrRS with the Tyr ligand shown in the binding site.
Although the sequence identity is 32.1%, the general folding is
very similar for the two proteins. The backbone structure,
predicted with STRUCTFAST, led to an initial coordinate rms
(Crms) difference in the main chain atoms between the two
superimposed structures of 0.64 Å before structure optimization.
After the side-chain optimization, the Crms (main chain) in-
creases to 1.75 Å for the 139 residues aligned structurally.
However, the conserved residues (Tyr-32, Tyr 151, Gln-155,
Asp-158, and Gln-173) in the binding sites have a Crms differ-
ence of 0.62 Å (all atoms except hydrogens). These comparisons
were made with the DALI structural-alignment program (19) to
superimpose structures.
The main difference between the two structures is that
M.jann-TyrRS lacks the -helical domain present in 4ts1 (resi-
dues 246–317). This domain is involved only in tRNA binding,
which is consistent with the observation that M.jann exhibits only
a minimalist tRNA anticodon loop-binding domain (32).
For M.jann-TyrRS, the tyrosine ligand binds in the deep cleft
formed by several -helices and -strands in the  domain. The
phenolic hydroxyl group of the Tyr ligand makes hydrogen bonds
with Tyr-32-O	 and Asp-158-O
1, both with a hydrogen bond
distance of 2.87 Å. The amino group of the ligand tyrosine makes
three hydrogen bonds with Tyr-151-O	, Gln-155-O1, and Gln-173-
O1. Table 1 lists the hydrogen bond distances that the Tyr ligand
makes in the binding pocket. Comparison of these distances with
the 4ts1 structure (see Table 1) shows that the hydrogen bonds
Table 1. Hydrogen bonds in the binding site of the predicted
M.jann-TyrRS structure, compared with the hydrogen bonds in
B.sther-TyrRS crystal structure (PDB ID code 4ts1)
M.jann-TyrRS B.sther-TyrRS (4ts1)
Ligand
atoms Protein atom
HB distance,
Å Protein atom
HB distance,
Å*
O	 Tyr-32 O	 2.80 Tyr-34 O	 2.93 (2.87)
O	 Asp-158 O
1 3.02 Asp-176 O
1 2.27 (2.83)
N Gln-75 O1 3.14 Asp-78 O
1 2.91 (2.87)
N Tyr-151 O	 2.83 Tyr-169 O	 2.78 (2.94)
N Gln-173 O1 3.12 Gln-173 O1 3.13 (3.28)
OXT Gln-75 N2 5.56† Lys-82 N 4.83 (4.97)†
*The values quoted here are from the crystal structure for B.sther-TyrRS (PDB
ID code 4ts1). The values in parentheses are after minimization with the
DREIDING force field.
†Water mediated hydrogen bonds (HB).
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made by the Tyr ligand are very similar. After publication, the PDB
coordinates for the predicted M.jann-TyrRS structure can be
downloaded from the Molecular Simulation Center publication
section at http:www.wag.caltech.edu.
Docking of the 20 Amino Acids to M.jann-TyrRS. Table 2 shows the
binding energies of all 20 amino acids when docked into the
predicted M.jann-TyrRS structure. Here we first build the amino
acid into the structure as in step 1. Further, we optimize the ligand
with protein fixed and then optimize the neighboring ligands with
the more distant residues fixed. Finally, all atoms of the protein
were optimized, without constrain. All these calculations included
the forces due to solvation by means of the SGB continuum solvent
method. As expected, the wild-type ligand Tyr has a much higher
binding energy (16 kcalmol) than any other natural amino acid.
Because several steps are involved in the activation of aaRS (29),
of which selective binding of the amino acid is only one, we cannot
be certain that only the natural ligand is bound strongly. However,
TyrRS is known to activate only Tyr and exhibits high selectivity
even in the binding of the amino acid (28, 29). Hence, it is plausible
that only the Tyr is bound strongly, as predicted in Table 2. Thus,
we consider that the results in Table 2 validate the accuracy of the
predicted structure for M.jann-TyrRS.
Design of Mutant M.jann-TyrRS for OMe-Tyr. Starting with the
predicted structure for M.jann-TyrRS, we used the COP algo-
rithm to design mutants of M.jann-TyrRS for selective binding of
OMe-Tyr (see Scheme 1).
OMe-Tyr has two equally favorable rotamers, one shown in
Scheme 1 (denoted 1 and the other with theOMe group pointed
down (denoted 2). Both rotamers were matched in the binding site
of Tyr in wild-type M.jann-TyrRS, keeping the zwitterion end fixed
in the structure. Component analysis of the energy contribution of
each residue in the binding site to the binding of OMe-Tyr was
calculated with Eq. 2. The binding site was defined as the entire
residue for all atoms of the protein within 6 Å of any atom of the
ligand, leading to the 26 residues in Table 3. Because rotamer 2 had
severe clashes with protein backbone of Gly-34 and rotamer 1 had
none, we considered only rotamer 1 further.
The nonbond interaction energies between OMe-Tyr and
residues within 6 Å of the ligand are summarized in Table 3. We
find that Asp-158 has a very severe clash with the OMe-Tyr, and
hence this residue was selected to be mutated to favor OMe-Tyr.
In addition, Tyr-32 has a strong binding contribution to Tyr over
OMe-Tyr and hence we targeted Tyr-32 for mutations to find a
residue favorable for OMe-Tyr.
We considered all 20 amino acids as possible mutations for
both Tyr-32 and Asp-158, and selected for further study all those
that favor OMe-Tyr over Tyr. The results for the six most
favorable mutations are shown in Table 4. The following choices
Table 2. Binding energies (including solvation) for the 20 natural
amino acids docked to the binding site of the predicted
structure for M.jann-TyrRS
Amino
acid
Binding energy,
kcalmol
Amino
acid
Binding energy,
kcalmol
Tyr 43.8 Val 16.2
Ala 27.2 Ile 14.1
Asn 27.2 Leu 12.0
His 27.1 Gln 9.7
Thr 26.8 Arg 2.3
Phe 26.6 Pro 1.3
Ser 25.6 Glu 3.5
Gly 24.1 Met 13.8
Cys 22.9 Trp 20.6
Asp 16.4 Lys 56.9
Scheme 1. Tyr and the analog OMe-Tyr (rotamer 1) for which the mutant
TyrRS was designed.
Table 3. Interaction energies of OMe-Tyr ligand (both rotamers)
and of Tyr ligand with the predicted structure (wild type)
of M.jann-TyrRS
Residue OMe-Tyr (rotamer 1) OMe-Tyr (rotamer 2) Tyr Diff‡
Gln-155 11.15 10.65 10.66 0.48
Met-154 0.93 0.60 0.60 0.32
Ala-67 1.69 1.43 1.42 0.27
Gln-109 0.99 0.91 0.91 0.08
Leu-66 0.21 0.13 0.13 0.08
Asn-157 0.13 0.20 0.20 0.08
Val-156 0.24 0.17 0.17 0.07
Phe-108 0.16 0.10 0.10 0.06
Leu-65 1.28 265.94* 1.23 0.05
His-160 0.25 0.21 0.21 0.04
Gly-105 0.08 0.03 0.03 0.04
Phe-35 1.52 1.50 1.49 0.04
Pro-152 0.32 0.28 0.28 0.04
Ile-159 0.05 0.02 0.02 0.03
Ile-33 0.23 0.21 0.20 0.03
His-70 2.89 2.87 2.88 0.01
Tyr-161 0.08 0.06 0.07 0.01
His-177 0.38 0.39 0.37 0.01
Leu-69 0.02 0.02 0.02 0.00
Gly-34 2.04 302.84† 2.06 0.02
Gln-173 11.15 11.20 11.17 0.03
Asp-68 0.94 0.98 0.97 0.03
Tyr-151 9.44 9.52 9.66 0.21
Glu-36 1.14 1.27 1.36 0.22
Tyr-32 13.45 12745.3* 15.69 2.25
Asp-158 2450.97* 0.80 15.44 2466.41
The interactions are shown for all ligands with any atom within 6 Å of the
Tyr (referred to as the binding site).
*Large van der Waals energy showing steric clashes of protein side chain with
OMe-Tyr ligand.
†Steric clash with main chain.
‡Difference between OMe-Tyr rotamer 1 and Tyr.
Table 4. Binding scores of the best 6 mutations for Tyr-32 and
Asp-158 in M.jann-TyrRS
Tyr-32 Tyr OMe-Tyr Diff
Glu 0.13 0.28 0.41
Asp 0.14 0.37 0.23
Gln 0.10 0.28 0.18
Met 0.32 0.37 0.05
Phe 0.45 0.49 0.04
Ser 0.08 0.07 0.01
Asp-158
Ala 0.41 0.92 0.51
Gly 0.26 0.08 0.18
Ser 0.52 2.68 3.20
Cys 0.99 4.88 5.87
Asp 1.70 4.36 6.06
Asn 0.64 10.54 11.18
Scores (in kcalmol) are nonbond interaction energies of the mutated
residue with the OMe-Tyr or Tyr. Based on these results, we selected the 5
mutations with negative difference for Tyr-32, and the one case for Asp-158.
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minimize clashes (stage 1): for Tyr-32: Glu, Asp, Gln, Phe, and
Met; for Asp-158: Ala.
In stage 2, we used SCWRL to generate the side-chain configu-
rations for the two mutated residues for each of the five cases of
simultaneous mutations selected from stage 1 (with five choices for
Tyr-32 and 1 for Asp-158). These side chains were optimized
separately for the analog and for Tyr in the binding site. This
optimization led to 5 full protein structures for each ligand. We then
carried out energy minimization of the new side chains with all other
atoms fixed, followed by energy minimization of the whole protein
with either OMe-Tyr or Tyr bound for all five mutants. The binding
energies (including solvation) for both OMe-Tyr and Tyr were then
calculated for all mutants. This calculation led to the binding
energies in the top half of Table 5 for OMe-Tyr and Tyr bound to
the five mutants.
The results for the five mutant proteins can be compared with
the wild type (given in the top row of numbers in Table 5), which
leads to 44 kcalmol for Tyr but 12 kcalmol for OMe-Tyr. All
five mutants bind Tyr less strongly (38–42 kcalmol) whereas
these five mutants bind OMe-Tyr by 37–49 kcalmol. Of the five
mutants, three favor binding of OMe-Tyr over Tyr by at least 5
kcalmol. These are [Y32Q, D158A], [Y32M, D158A], and
[Y32D, D158A], which lead to total binding energy for OMe-Tyr
of 49, 44, and 44 and differential binding energies of 7, 5, and 6
kcalmol. The other two cases both lead to weak binding and
favor Tyr over OMe-Tyr, hence we will ignore them.
Fig. 2 shows the predicted binding site of OMe-Tyr for the best
case, [Y32Q, D158A]. We see that residues Ala-67, Ala-158, and
Leu-65 form a hydrophobic pocket for the methyl group. The amide
N2 of Gln-32 has close contact with the oxygen atom of the OMe
group (3.79 Å), whereas the O1 atom of Gln-32 is stabilized by
forming a weak hydrogen bond (3.58 Å) with the main chain NH
of Leu-65. These H-bonds might be stabilized further by an
intervening water.
The mutant [Y32M, D158A] is also a favorable candidate.
However, for [Y32D, D158A], the charged group of the Asp does
not seem to have a favorable stabilization of the charged group,
which may lead to problems with folding.
Comparison to Experimental Results. Wang et al. (16) carried out a
combinatorial experiment to find a mutant M.jann-TyrRS opti-
mum for OMe-Tyr. Because no three-dimensional structure was
available they used a sequence alignment with 4ts1. Their
alignment suggested that the five residues—Y32, D158, E107,
L162, and I159—are in the active site. They then considered all
520 mutations and selected the best ones. This selection was
carried out by first screening for binding any amino acid followed
by screening against natural amino acids to find the mutants least
able to bind Tyr and any other natural amino acids. Of these the
ones that were most selective toward OMe-Tyr were considered.
These studies led to [Y32Q, D158A, E107T, L162P, I159I].
Thus, the experiments identify the [Y32Q, D158A] replace-
ments found from COP to be best.
However, Wang et al. (16) found their optimum mutant to also
include E107T and L162P (they found that I159 did not change).
We did not consider mutations of E107 or L162 because our
predicted structure for M.jann-TyrRS places both residues far from
the binding site (see Fig. 3). Thus we find that Glu-107 is on the
Table 5. Binding energies of OMe-Tyr and Tyr to the wild-type
M.jann-TyrRS and mutants
Y32 D158 E107 L162
OMe-Tyr,
kcalmol
Tyr,
kcalmol
Differential,
OMe-TyrTyr
Y D E L 12.34 43.83 56.17*
E A 37.11 37.64 0.54
D A 43.85 38.24 5.60†
Q A 48.93 42.30 6.62†
F A 39.06 39.81 0.76
M A 44.17 39.00 5.16†
E A T P 27.48 34.98 7.51
D A T P 31.65 25.58 6.06
Q A T P 27.06 17.72 9.33‡
F A T P 31.54 34.06 2.53
M A T P 27.20 28.69 1.50
The first row is for the wild type, which binds Tyr well but not OMe-Tyr. The
next five rows consider the mutations for Y32 and D158 identified in Table 4.
The three cases denoted as † are considered to be promising cases worth
testing. The last five rows consider these same five mutations, but with the
E107T and L162P mutations observed in the experiments. The case denoted as
‡ is the one determined experimentally.
*Wild-type M.jann-TyrRS.
†Chosen designed mutant M.jann-TyrRS.
‡Mutant M.jann-TyrRS found experimentally (ref. 16).
Fig. 2. The predicted binding site surrounding the OMe-Tyr in the COP-
designed mutant [Y32Q, D158A] M.jann-TyrRS. The mutated residues (Gln-32
and Ala-158) are labeled in blue. Ala-67, Ala-158, and Leu-65 form a hydro-
phobic pocket for the methyl group. The amide N2 of Gln-32 has close contact
with the oxygen of OMe, whereas the O1 atom of Gln-32 is stabilized by
forming a weak hydrogen bond (3.58 Å) with the main chain NH of Leu-65.
(Both may have intervening water molecules.)
Fig. 3. The predicted structure for M.jann-TyrRS with explicit side chains for
the Tyr-32, Asp-158 residues involved in the design. The Tyr ligand is also
shown (labeled in red). The predicted position of residues Glu-107 and Leu-62
(labeled in blue) M.jann-TyrRS are shown.
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surface of the protein, 12.9 Å from the Tyr ligand (from the C of
Glu-107 to the O	 of Tyr ligand), and Leu-162 is 14.5 Å from the
Tyr ligand. In the Wang et al. alignment, Leu-162 and Glu-107 in
M.jann-TyrRS correspond to Leu-180 and Asn-123 in the 4ts1
structure. Leu-180 is in the middle of a -strand on the bottom of
the binding site in 4ts1. The Leu 3 Pro mutation at this position
would be expected to disrupt the secondary structure. Because
Asn-123 is close to the core of the protein in 4ts1, it seems unlikely
that a charged Glu would fold into this structure.
Because our predicted structure puts the residues Glu-107 and
Leu-162 well outside the binding site for M.jann-TyrRS, COP did
not find these residues as mutation targets.
To understand why the combinatorial experiments led to a
different result than the COP design, we calculated the effect of
including the [E107T, L162P] mutations along with the five cases
from the COP analysis. The L162P mutation requires a change in
the main chain conformation, and therefore we carried out anneal-
ing MD to optimize the backbone structure. Hence, the energy
minimization was followed by one cycle of annealing MD with SGB
solvation method, using MPSIM. The resulting best-energy annealed
protein structure was used to calculate binding energies.
The calculated binding energies of both OMe-Tyr and Tyr to the
mutants with the five mutations are shown in the bottom half of
Table 5. We find that the experimental optimum mutation, [Y32Q,
D158A, E107T, L162P], leads to a dramatically weak binding (18
kcalmol) to Tyr. Because the experiments conducted negative
selections against any mutant TyrRS that binds Tyr, our favored
mutants, which have higher affinity to Tyr, would be screened out
in this process. We find also that the experimental mutant leads to
a differential preference for OMe-Tyr over Tyr of 9 kcalmol. This
is by far the best differential we have seen and much better than for
our designed case. However, the net binding of OMe-Tyr to the
mutant is calculated to be only 27 kcalmol. This finding could
explain the observation that the mutant led to an incorporation rate
much poorer than for the natural amino acid. Thus, the calculations
do seem consistent with the experiment given how the experiment
was carried out.
Because our predicted mutants all would have been in the
experimental screen, it would be interesting to reexamine the
three cases predicted by COP to determine how effective they
are. We suspect that the predicted differentials of 5–7 kcalmol
may be sufficient to obtain selectivity. In addition, the total
binding energies of 44–49 kcalmol for OMe-Tyr suggest that
these new mutants would be much more active.
Summary
We describe a generic structure-based rational functional site-
design procedure (COP) to design mutant proteins that would bind
optimally and preferentially to new ligands and we apply this
procedure to predict mutant M.jann-TyrRS proteins optimal for
binding OMe-Tyr. This procedure leads to a mutant, [Y32Q-
D158A] (and two others), predicted to have a good preferential
binding over Tyr and an excellent absolute binding energy to
OMe-Tyr.
We compare our predictions with the experimentally opti-
mized mutant [Y32Q-D158A-E107T-L162]. Experiment and
theory agree with the [Y32Q-D158A] mutations. However, we
predict that residues E107 and L162 are remote from the binding
sites. We find that these mutations lead to extremely poor
binding of Tyr but to an extremely high differential binding of
OMe-Tyr over Tyr, which is what the experiments were designed
to do. However, we calculate that the activity of the experimental
mutant is far lower than the designed one. Because our predicted
mutation is a subset of the ones considered in the experiments,
it would be interesting to test the selectivity and incorporation
efficiency for our three predicted cases.
Because no experimental three-dimensional structure was avail-
able for wild-type M.jann-TyrRS, we used STRUCTFAST to predict
the alignment and backbone folding. We then used a series of
energy minimization and annealing calculations to obtain the
structure for the full protein. We found that this predicted protein
structure binds Tyr much stronger then the other 19 natural amino
acids, which we consider as validation of the predicted structure. In
addition, the success in predicting mutants that compare consis-
tently with experiment provides additional evidence in favor of the
predicted structure for M.jann-TyrRS
The experimental comparison of our predicted mutations with
observed incorporation would provide additional tests of the
validity of these new structure-prediction tools.
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